Omega3 and Vit D evaluation on pregnancies with fetal growth restriction

Abstract

Fetal growth restriction (FGR), which can be set when the fetal weight is below the 10th percentile, is complication that affects 5-10% of pregnancies and is the second leading cause of perinatal mortality. There is, at present, effective therapeutic intervention can reverse or at least stop the progressive course of placental insufficiency. The monitoring is to optimize the service and decide the appropriate time of delivery, comparing the risks of prematurity and those arising from acidemia with intrauterine permanence. In this context arises as a therapeutic option using the Omega 3 (É3) fatty acid (FA) capable of promoting the development and growth of the fetus. The FA É3 and É6 are eicosanoid precursors - lipid source mediators that modulate the inflammatory and immune response. The FA can influence the production of cytokines and tissue response. In general, FA É3 reduce the systemic inflammatory response and the FA É6 increase. The eicosanoids derived É3 FA metabolism, such as the 3 series prostaglandins, 5-series leukotrienes, and thromboxane A3, have less effect on the inflammation and increased defense mechanism of the immune system (“ PGE2). Objectives: This study aims to evaluate the interference of Omega 3 in pregnancies with RCF. For this, we will hold the first dose of É3 and É6 AG in pregnant women with and without RCF and confront the results to determine whether there is a deficit of É3 in pregnancies with RCF. It is also objective of this study was to evaluate the interference Omega 3 Administration in the growth of the fetus during pregnancy. Method: Cross-sectional case-control study. They will be analyzed for two years all patients between 24-37 weeks with ultrasound diagnosis of fetal growth restriction (birth weight below P10) accompanied by the UNIFESP outpatient. We will hold the dosage of total cholesterol and fractions (LDL and HDL), triglycerides, Omega 3 - alpha-linolenic (ALA) and Docosahexaenoic (DHA) and Eicosapentaenoic (EPA) and Omega 6 - linoleic (LA) and Arachidonic (AA). Subsequently we will manage Omega 3 (300 mg DHA + EPA 120 mg) to half of patients in each group (the other half received placebo). It will be assessed by ultrasound to estimate fetal weight in all these pregnant women every two weeks. Later we evaluate and confront the groups to determine whether or not gain significant fetal weight in those who received Omega 3. (AU)